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August 30, 1985

The Honorable Members of the California State Senate:
We would like to call your attention to the attached report,
Silicon Valley II: A Review of State Biotechnology Development
Incentives, which was prepared by the Senate Office of Research.
The report focuses on the intense competition that is developing
between the states to attract and encourage the growth of the
biotechnology industry.
This exciting new industry has grown from nothing to over two
hundred firms in less than ten years. Its continuing growth and
prosperity is important to California for two reasons. First,
promises new jobs for our growing workforce and economic development for our cities. Secondly, advances in biotechnology will
result in new products and processes that will improve health,
increase productivity, and enhance living standards across the
board. Biotechnology applications will affect virtually every
sector of our economy as well, from agriculture to waste
management.
promise of this new industry, however, has not gone unnoticed
state development officials around the country~ The attached
report documents many of the very active steps tbat~ther states
are takingyto promote the development of biotechnology within
bord~rs, and demonstrates the increasing sophistication
the economic development strategies that are being employed by
those states.
California is not in any imminent danger of losing
%
the biotechnology industry, state policy makers need to
aware of its importance to California and the increasing comthat we are facing. With this background in mind, we
need to review the state's commitment of resources and
to ensure that California will maintain its leadership
tion in biotechnology.
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pro Tempore
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PREFACE

The growing interest of other states in promoting the development
of biotechnology has not escaped the notice of either state officials or private industry in Cali
Increasing concerns of
California legislators and private representatives about the
growing competition and regulatory climate for biotechnology
culminated in the passage in August, 1984, of Assembly Concurrent
Resolution No.170. The measure was authored by Assemblyman Sam
Farr with Assemblyman Robert Naylor as principal coauthor. Senators David Roberti and Rose Ann Vuich were Senate coauthors.
ACR 170 called for two studies, specifically requesting:
1.

"the Assembly Office of Research to conduct a study, to be
completed by April 15, 1985, reviewing all existing, pending,
and elapsed federal and state regulations affecting the California biotechnology industry"; and

2.

"that the Assemb
ce of Research and the Senate Office
of Research also study incentives being offered by other
states and countries to promote .the development of biotechnology industry
thin those states and countries."

The first request was met with the publication of Review of
Federal and State Regulations Affecting the California Biotechnology Industry, by James W. Rote, Assembly Office of Research,
April 1985.
This report is in response to the second study request. A draft
version was distributed to members of the Advisory Committee
es
lished pursuant to ACR 170, to Lieutenant Governor Leo
McCarthy's
c Development
sion, the California Economic Development Corporation,
other interested parties. The
final version bene tted considerably from the comments received
members of these groups. The author wishes to
ir contribu
, especially those from Norman
and Nan Newell of Calgene, Assemblyman Sam Farr, Peter
Staple of Cetus Corporation,
an Cunningham of Genetech, Inc.,
and James W. Rote of the Assembly Office of Research. Any remaining errors and shortcomings in the report remain the
responsibility of the author.
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EXECUTIVE SUMMARY

EXECUTIVE SUMMARY

During the last decade new discoveries and scientific developments involving recombinant DNA and cell fusion have given birth
to a rapidly growing new industry called biotechnology.

The

number of newly established biotechnology firms now exceeds 200,
and various estimates place 30-35% of them in California.
Several other states across the country have shown keen interest
in the development of biotechnology and have instituted a number
of programs to attract expanding biotechnology firms.

In

addition, some states have taken major steps designed to "grow
the industry" rather than just entice a few plant locations.
These steps include expanding state support for biotechnology
research and development at state universities as well as in
private firms, increased state funding for university biotechnology education and training programs, and the establishment of
state programs to provide financial and technical assistance to
biotechnology firms.
States with the most ambitious biotechnology programs -- such as
North Carolina and New Jersey -- have also created biotechnology
centers which offer a wide variety of incentives and assistance
to biotechnology firms.

In addition to the above noted programs,

these centers provide the industry with improved access to university research and technology, technical and financial assistance, and incubator space and facilities.

In some states the

centers are operated by universities; in others, they operate as
nonpro

t institutions separate from any single university.

In

all cases, the centers strive to link the resources and research
of universities to the needs of private industry.

In addition,

they emphasize interdisciplinary, intercampus research.

Funding

is typically provided through state, federal, and private industry sources.

The strategies that individual states are applying

pursuit

of biotechnology are a good deal more sophisticated and better
funded than past state economic development strategies.

While it

is too early to evaluate the effectiveness of the various state
efforts, the degree of sophistication, the levels of funding, and
the fact that many feature public-private cooperation with substantial sums of private financing all suggest that these states
will be successful in attracting biotechnology firms to and fostering the development of new biotechnology firms within their
borders.
There are several reasons why the State of California may want to
respond to the competitive challenge from other states.

First,

California is likely to lose plant expansions, new firms, and
employment to other states unless it responds adequately.
Secondly, the industry is in need of additional research and
development, education and training, and other services of which
state government is the principal provider.

Third, advances in

biotechnology will bestow an enormous range of benefits to
society in agriculture, health, forestry, fisheries, pollution
control and hazardous waste management, all of which are very
important to the State of California.
The options open to the State to assist the industry are relatively straight forward:

(1) increase biotechnology R&D;

(2) expand education and training in fields related to biotechnology; and (3) establish programs to help the industry meet
regulatory requirements and to increase public awareness of the
nature of and benefits to the biotechnology industry.
of the state's options is presented on page 36.
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CHAPTER I:
INTRODUCTION

Biotechnology, broadly defined, includes any technique
that uses living organisms {or parts of organisms) to
make or modify products, to improve plants or animals,
or to develop microorganisms for specific uses. 1
Background
While biological processes and organisms have been used for centuries, for example in baking, brewing, and farming, scientific
breakthroughs in the last decade have revolutionized the field.
New discoveries and developments in biotechnology, including
recombinant DNA, cell fusion, and novel bioprocessing techniques,
offer limitless potential for new and improved products, new
processes for industry, and indeed, whole new industries.

The

new biotechnology may, in fact, be the most significant technological revolution of this century when judged in terms of its
potential impact.
The range of industries which will be affected by new biotechnology products and processes is staggering.

The first and most

important area is medicine where the production of insulin,
feron, monoclonal antibody diagnostics, and various vaccines
hold tremendous promise.

In agriculture, researchers are engi-

new crop species which will be resistant to stress,
he

s, and pesticides and will grow more rapidly.

New

micro-organisms are being developed to inhibit frost formation to
reduce frost damage to plants.

New organisms and techniques will

to enhanced oil recovery, help control pollution, degrade
tox

waste, and bring other environmental benefits.

The chemi-

cal industry and food additives will be affected by the new
biotechnology.

So will electronics with the potential develop-

ment of biosensors and biochips -- devices that would act as
semiconductors using protein molecules.
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Many of the promising applications of biotechnology, such as
biochips, will not be realized for years, possibly decades.
Nonetheless, the potential benefits are overwhelming and a new
industry is rapidly emerging.

Beginning in the mid-1970s, entre-

preneurs from the scientific community began to establish new
firms to capitalize on the breakthroughs in biotechnology.

The

pace of commercialization was particularly rapid in the United
States, where in less than ten years more than 200 new biotechnology firms were established.*
The initial spurt of growth in the biotechnology industry has not
yet yielded much in the way of job creation, production, or other
economic development.

Nonetheless, it has caught the attention

of an increasing number of state economic development officials,
governors, and legislatures.

One reason for this attention is

that the initial public offerings by two biotechnology firms set
Wall Street records and received widespread publicity.

Genen-

tech's initial offering in 1980 set a record for the fastest rate
of increase in the price of stock (from $35 to $89 in twenty
minutes).

In 1981, Cetus raised $115 million on Wall Street, a

record for initial public offerings at that time.
A second reason for the increased interest of state officials was
that the emergence of biotechnology as a potentially large new
industry coincided with the rapid growth of new state initiatives

*Various estimates show California with approximately 35% of
these firms.
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to promote, develop, and attract high technology businesses.
r to 1980, only four states -- Massachusetts, North Carolina,
Connecticut and Florida -- had programs for the development of
science and technology-based industry.

Today, at least 33 states

have programs aimed at developing high technology industry.

Five

of the remaining 17 states are launching high technology develop2
ment programs, and several others are in the planning stage.
The rapid growth of state programs targeted at high technology
industry can be explained by a number of factors.

The tremendous

growth of the electronics and computer industries in California
and Massachusetts produced countless economic benefits for those
states which, in turn, prompted economic development officials in
many of the other states to try to duplicate that success within
their own states.

Another factor was economic hard times.

Fol-

lowing the extended recovery from 1975-1979, the U.S. economy
went through a series of ups and downs culminating in the 1982-83
recession, the most severe recession that the
enced since the 1930s.

u.s.

has experi-

On top of these short-term swings, the

U.S. economy was (and may still be) undergoing a secular decline
in the importance and strength of many of its basic industries,
including autos, steel, and rubber, primarily as the result of
increasing international competition.

The tremendous declines in

employment that occurred, particularly in the industrial heartland,

state of

development s

ls to adopt or modify their economic
s in

to pursue new industry and jobs

to replace the losses.
A third factor involves the development of federal initiatives to
stimulate state programs.

In 1979-80, for example, the U.S.

Department of Commerce offered several million dollars in matching grants to state programs set up to provide financial assistance to firms engaged in developing innovative technologies.
Four states -- California, Indiana, New York and Connecticut --

CHAPTER I.
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established innovation
tiative.

under this ini-

The new state programs targeted at

technology were, at least
initially, outgrowths of traditional economic development pro-

grams. As such, the emphasis was on
expand or locate new facilities in
the early strategies were real

business firms to
states. In other words,

marketing programs.

le Cali-

fornia did very little marketing at
time,
saw plenty of
evidence of the marketing efforts of other states. A number of
them sent delegations -- some led by governors -- into Silicon
Valley to entice California firms to expand or relocate their
facilities in their states.
During this period California lost a signi
number of jobs
and plant expansions (and some firms) to other states and countries.

Some of those losses were widely and prominently adver-

sed, such as

Dow

1 petrochemical

County and the transfer of
Despite these

in Solano

by Atari to Taiwan.
has continued to generate new

ses,

firms and jobs at a c

1

that

consistently outpaced the rest

of the country for the past decade.
to expla
California's
A number of reasons have been offe
larly the success of
s high
continued economic success,
technology sectors:
{1) the excel
of
s
educational
institutions, pub
the
entrepreneurial c

c and

, and the

and qual

of
an

that has fostered risk-taking and has

encouraged entrepreneurs to move new products and processes out
of the research
s; (3)
abil
of the state to attract
labor, particularly skil
workers and scienti
and engineering personnel; and, (4) the availability of financing for new and
expanding firms, primarily

the form of venture capital.
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useful for

programs

no

particu

i

1

targeted to biotechincentive programs.

contacts helped flesh out

1

details

, and other aspects of the

programs re
These surveys
a useful starting point, but all suffered
from a common limitation -- that of sorting out state biotechnology initiat

from those designed to promote economic devel-

opment in general or even those more narrowly targeted to the
development of
technology. A decision was made not to
restrict the study to just those programs that have been established to foster the development of biotechnology.

Such an

approach would be too narrow in scope and would pass over a number of programs that have been initiated by states to foster the
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ment (OTA) and published in 1984.

That report identified ten

factors of potential importance in the international competitiveness of biotechnology.
tance are: 5
•
•
•
•
•
•
•
•
•
•

The ten factors in rough order of impor-

financing and tax incentives for firms
government funding for basic and applied research
personnel availability and training
health, safety, and environmental regulation
intellectual property law
university/industry relationships
antitrust law
international technology transfer, investment and trade
targeting policies in biotechnology
public perception

This list of factors served as the starting point for categorizing state biotechnology incentives for this chapter.
adjustments to the list were subsequently made.

Three

First, the fac-

tors important solely to international comparison were eliminated.

The primary purpose of the OTA study was to analyze the

international competitiveness of biotechnology in the U.S. versus
Japan, West Germany, the United Kingdom, Switzerland, and France.
Hence, trade, technology transfer, and antitrust policies were
important in the OTA analysis.

These policies, however, tend to

be national, varying from country to country, but essentially
uniform across subnational jurisdictions such as states.
A second modification to the OTA list was the elimination of the
regulatory category since this was the subject of a separate
study requested by Assembly Concurrent Resolution 170.

A final

adjustment was made to accommodate novel categories of incentives
that states are offering.

CHAPTER I.

-10-

The resulting list contained the following six categories of
incentives, around which Chapter II is organized:
•
•
•
•
•
•

Financial assistance -- direct
Financial assistance -- indirect
Information and technical assistance services
Research and development
Education and training
Technology centers

As the reader will no doubt discover, the list is still somewhat
arbitrary, and the categories are not necessarily mutually-exclusive.

Moreover, some state programs could be listed under one or

more of the categories.

In fact, some state programs are multi-

purpose and thereby fall into several of the categories.

An

effort was made to avoid double counting by sorting the programs
on the basis of their primary function and listing them only
once.

Most of the multipurpose programs are described under the

final category, technology centers.

CHAPTER II:
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CHAPTER II:
STATE BIOTECHNOLOGY INCENTIVES
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More traditional loan programs targeted to high technology firms
have also been started in several states as a result of a pilot
federal program in the late 1970s and early 1980s.

Included in

this category are the California Innovation Development Loan
Program, the Connecticut Innovation Development Loan Fund, and
the Corporation for Innovation Development in New York.

These

programs are evidence of the shift in development strategies that
has occurred; their objective is to foster the development of new
technology through loans to relatively young firms, rather than
simply providing loans to the more traditional business recipients.

The programs, however, have been hampered by a lack of

funding -- initial capitalization for each corporation was only
$1 to $2 million.
Financial Assistance -- Indirect
The lack of adequate funding for the innovation development loan
programs is symptomatic of the reluctance of state governments to
provide direct financial assistance to business firms.

States

have been less hesitant to offer indirect financial assistance,
especially through tax incentives, which leave the actual financing decisions in the hands of private investors.
Since nearly every state offers one kind of tax incentive or
another for business expansion, it would be difficult and of
little use to catalogue those incentives here.

Three recent tax

incentives targeted to the development of high technology companies are, however, noteworthy.

The State of Indiana allows a tax

credit of 30% on individual investments in a venture capital pool
that is administered by a state-chartered, privately-owned, nonprofit Corporation for Innovation Development. The pool is pri4
vately funded with no state contributions.
Minnesota recently
enacted a tax credit of 30% of the value of the technology transfer that occurs when a small business is spun off from a parent
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University to conduct biotechnology research on new and improved
crop strains, to improve biotechnology training methods for students, and to create a science base that will simulate the growth
of biotechnology

in Indiana.
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and cellular biology at Indiana University received $1.2 million
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for cellular research and to clone rare gene sequences for
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s, and other high
centers for biotechnology are
a wide variety of
including
training, access
transfer, technical assistance, and incubator space and
In some states the
centers are operated
, they
rate as
nonpro t institutions separate
single university. In
all cases the centers strive to link
resources and research
of universities to the needs and
s of private industry.
Funding is
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provided
conjunction with
contributions
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Most centers also actively
recruit federal funds
research
ects, facilities, equipment, and other programs of
centers.

Initially set
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e
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pro
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incentives and assistance to
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to university research

.
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flagship of state technology centers.
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biotechnology development
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s research grant pro-
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facility to carry out

responsibilities.
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tional funds are to be sought from public and private
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sources.
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scope and magnitude.
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$42

for the es
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, 1984.

lishment and construction of a net-

of advanced
private

Key features of

centers at the state's public and

titutions of higher education which may include,

but are not limited to centers in biotechnology, food science,
hazardous and taxies substance management, and industrial
ceramics;
•

$15 million for advanced technology centers in areas of future
economic development;*

•

$23 million for the construction and improvement of undergrad-

uate technology and engineering facil
h

r technology job training

ies and equipment for

retraining programs to be

among the county col
pub
•

, private higher

r education institutions;

h

of Higher Edu-

$10

ca

community col-

ssage, four bil s were introduced in the
to enact specific provisions of the

slat
Act.

One of

lls, Senate
s

Techno
ss

s

*

is

11 1654, establishes the

of,

had

to replace the
red.

new commis-

operate independently of, the New

Bond Act speci
that
establishment of an advanced
technology center shall include a commitment from industry to
finance a
of the center's operating costs.
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The ATCB is slated to

$20 million from the $90 million

bond issue and an additional $20 million from Rutgers University
and the Universi

of Medicine and Dentistry of New Jersey under

an independent bond issue.
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s and
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medical

are

state and

ointly funded by

Cornell center receives

11
Te
logy Foundation,
and so far has
have signed sixcontracts totalling $2.5
1
each. The medical biotechnology center at Stony Brook has 11 corporate sponsors. The
programs promote research productivity by concentrating researchers in one
lding,
so he s reduce costs by
allowing expensive equipment to
shared, and they stress interdisciplinary research. Program funds are to be used for faculty
research grants, recruiting
lty and setting up labs, centralized research facilities and specia
, educational programs
for faculty and industry, industry-faculty exchange, and services
and facilities to foster
establishment of small biotechnology
.
30
compan1es.
$1

Virginia -- The Commonwealth of Virginia has established a Center
for Innovative Technology to promote research, to foster
industry-university cooperation, and to serve as a broker between
industry and univers
research activities.
$19 mill

research needs and ongoing
The center has a two-year budget with

for j

ity research and develop-

ment at
Univers

! research institutions -- the

of

rginia Commonwealth

Univers

research and development in all
logy.31

technologies, not just
Maryland --

e

the Univers

of Maryland

ished a Biotechnology Institute at
will serve as an umbrella organ-

ization for a Center

Advanced Research in Biotechnology.

center is being set
university, industry

as a co
effort between the
and state, local, and federal governments

to focus on biomedi
tions. The center, which

The

biology, and agricultural applicacurrent

design phase, will
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Three conclusions emerge from the review of the incentives and
other programs that states are providing in their efforts to
attract and promote biotechnology.

(1)

A number of states are aggressively pursuing the new industry in order to attract firms, to encourage the development
of new

, and to foster the diffusion of new biotech-

nology products and
( 2)

The s

sses within their states.
states are applying in the pursuit of

s

biotechnology are a good deal more sophisticated and better
funded

deve
more

1

strategies, which have
efforts designed to

0

to

new

faci

s in their

states.
(3

It is too ear

to eva

the effectiveness of these bio-

efforts by the states.
are actual

s

A number of the incentive

sals,
The o

four

st

others are still in
are only three to

less, the degree of sophistication
f

fact

many

levels of funding, and the
-private cooperation with sub-

stantial sums of private corporate financing all suggest
these states will
no logy
techno

rms to

fos

successful

attracting biotech-

the development of new bioborders.
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At-a-Glance Options for Promoting Biotechnology
A.

Provide Financial Assistance to Biotechnology Firms

B.

Help Expand Biotechnology R&D Activity
1.
2.

R&D Tax Credit
Direct State Expenditures
a.
b.
c.

University R&D
Matching Grant Program
Grants to Small R&D Firms

c.

Increase Education and Training Funding

D.

Provide Technical Assistance and Information
1.
2.

E.

Public Education
Regulatory Assistance

Establish One or More Biotechnology Centers

Should the State of California Respond?
One school of thought argues that the best thing that state
government, indeed all government, can do is to stay out of the
way
the industry operate and prosper without any interor assistance.
success of Ca i

Proponents of this view often cite the

a's electronics and computer industries as

high technology industry can flourish without government.
s view is, of course, oversimplified and glosses over the role
government has played in the development of high technology
industries in this country.

The federal government, and to a

lesser extent, state governments, have funded much of the under-

s

research
c

cal

Cali
First, as
tries are
develop a
fornia expects to maintain
likely that it
11
to

s
se

Otherwise, it is likely to lose p
employment to other states.
A second reason the State should cons
biotechnology industry is current

in

responding is
of additional

research and development, education and training, and other
services of which state government is one of the principal providers.

A third reason is independent of the potential job

development benefits that biotechnology holds in store.
Biotechnology wil be one of, if not
techno
next two or three decades, and will
stow an enormous range
of bene
lture,
stry,
s to soc
fisheries, pollut
control,
hazardous waste management, all
of which are very important to the State of California.

*

Government regu
policies have also o
been a s
ficant factor in in
ing industrial
lopment.
are opposed to government assistance for biotechnology deve
opment are typically in favor of
ss regulation as well.
Since it is the subject of a separate report, recommendations
regarding regulatory policy will not be
1
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State Options for Promoting Biotechnology
A.

Provide Financial Assistance

Although a number of states have embarked upon programs to help
provide financial capital for high technology startups and expansions, there is at this point in time no such identified need in
California.

As noted earlier, California leads the country in

raising and committing venture capital, which is one reason that
the biotechnology industry has flourished in this State.

A sec-

ond argument against providing public capital is that the State
is probably not a better judge than private markets of the risks
and benefits of biotechnology investments.

Although some state

programs have been successfully implemented, they are relatively
small and unlikely to have much of an impact, if any, on the
development of the overall industry.
B.

Help Expand Biotechnology R&D Activity

Rather than provide financial assistance, the State could help
fund additional research and development either through an R&D
tax credit or through direct appropriations.

This option would

not only address an identified need of the biotechnology industry, it would help them to meet indirectly their needs for financ

1 capital.

The need for additional R&D has been articulated
OTA study 2 , in the incentives that other states are pro-

viding, in hearings before the California Assembly Committee on
3
Economic Development and New Technologies , and in meetings of
the ta

force established pursuant to Assembly Concurrent Reso4
lution 170 . Given the importance of stimulating additional R&D,

both the tax credit and direct expenditure approaches will be
addressed. 5

0

neces

actual re
s

sever a

•
•
•

Another

nt
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•

Scope of coverage is also a problem with the simple R&D tax
t. A substantial portion of R&D expenditures is directed
at product and package design and other marketing type goals.
There are no justifiable economic grounds for subsidizing such
activity, yet it is not clear how an R&D tax credit can be
designed to exclude those activities.

•

Another drawback to a straightforward tax credit for R&D
expenses is the potential revenue loss to the State. According to estimates by the U.S. Treasury Department, the federal
revenue loss from the 25% incremental federal tax credit is
$700 million per year.
If a similar credit were enacted in
California, at say a rate of 10% rather than the federal 25%
rate, it would reduce California's franchise tax and personal
income tax by some $35 to $50 million per year, according to
some estimates.

An alternative to the simple tax credit would be to grant tax
credits to private firms for contributions to specified R&D centers, including but probably not limited to biotechnology centers.

University-based research foundations would be the most

likely recipients of such contributions, but eligibility could be
extended to cover nonprofit industry research centers as well.
This type of tax credit nevertheless faces similar difficulties
as tax credit based on in-house research.

Dilution of state

incentive due to the federal tax code remains a severe obstacle.
The problem of defining acceptable R&D remains to some degree and
might be complicated by requiring a list of acceptable institutions to receive corporate donations, as well as designating what
ions can be used for.
2.
D

rect State Expenditures
state expenditures for basic and applied research is the

only general alternative to state tax credits as a method of
stimulating biotechnology R&D.
a number of ways.
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AsS<.·mbly Con<·urrcnt Ucsolution No. 170
HESOUJTIO:'\ CHAPTER 130
Asst•mhly O:mC'urn•nt Hc.-solution 1\o. l7U--Hdativc> to biotl'Ch·
nology.
IFilt'<l with

~'<'rt'lary

nl Stall' .\111£11'1 :11.

1~.1

I.E< :lSI AT I\ E ( :( )l ''SEI :s I> I< ;t·~\T

ACH 170. F<~rr. Hioh'!'hnology.
This mc>asurc> rc>qu«•sts the> Assl•mbly Offic<' of R<•sc>arch to conduct
a study, to be> complt'll'd by April 15. 19H5, f<'Vi<'wing ull <'Xisting.
p<•nding. ;llld <'lapsc>d f(•d<'rul ;mel stat(' rl'gul;.ations am.•cting th<·
( :alifornia biolPchnology industry so th<~t th<' Lc-gisluhm• can muk<'
infornwd cl<'cisions on hf}\\' to promote> th<' hiot<'Chnologr industry
whil<• proh.•cting public h<';.alth and s;.afc>ty and th<' l'll\'ironm<'nt.
WIIEHEAS. California is tlw int<'ll<•chml cc>nt<'r of th<' nation\
biukdmology industry: unci
WIIEHE:\S. Approximat<'ly 35o/(' uf llw nation's biol<'chnology
c·ompanil's, induding tlw IC'ading comp;.mi<'s. t.tr<' h<'adqmart<'rro in
( :alifornh1: and
WI IERK\S, Californiu c:umpanil'S han· air<'<tCiy d<'\·dopl'<l
products. such ;1s human insulin and proinsulin, und int<'rf~ron.
which han• tlw potential to alll•viatc hummt suff<'ring and illn<'Ss; and
\\'II ERE:\S. Biot<'<·hnological r<'sC'arch is \'ita I to Californiu 's
agricultural industry, offt•ring prosp('('ts of incn•as<'d production.
,.a<.·dm•s for anim;~l disc.•as<'s, dis<'aS<' rC'sistant food crops. drought
rPsist.mt plant strains. <llld mor<' nutritional foodstuffs: &Uld
\\'IIERE:\.S. Th<' llnit<.•d Stt.~l('s P;lt<'nl ilncl Trad<'nwrk Offi<·<' has
rt'('l'in•d in rPC('Ill Y<'<~rs IW<trl~· one> thous.md pat<'nl applications
bHsPd on biotC'chnological n's<'arch: ;,mel
WI IEREAS. Tlw bioh•dmology fidd is Ji!rowin~ mor<' cnmJwtitiw.
particular!~· with r<'sp<'Ct to Pacific Rim ;.mel Europ<'<m countri<•s
<~ccording to tlw Congrc.•ssional OITicC' of Tl'Chnology
Assc.•ssnwnt. prh·att.• und public compuni<'s som<'timcs be-nefit from
gnn•num•nl subsidi<'s: uml
WIIEHK\S. Tht> St:ah' of C;llilcmJia should t>xplon• appropriat<'
nwthods of assisting tlw stah··s biott'Chnology industr~·: .mel
\\'IIERE.\S. 'umc>rous fC'dNal and statC' <tgl'llci<'s. including thC'
'atiunallnstitutc>s of llt••alth and Envirmum•ntal Proh'Ction :\~Pncy.
tlw Statt• Dt•partm<'nt of Food and :\grkulhm•. and the Stat<'
Dt•p;trhllt'llt of Ul'<llth St•n·ict•s. <ldminish•r c.•n\'ironm<'ntal and
lwallh rc>gulations afl<-cting biotl•chnology r<'st•arch ;md applications: .

and
\\'IIEHE:\S. Tht•st' r<'~ulations han• succc>ssfully prolt't't<•d without
incidt•nt the public ·s h<'alt h and saft•ty and the <'m·ironment during

'l'i
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